Editing Genentech (section)

==Research==
Genentech is a pioneering research-driven [[biotechnology]] company<ref name=NYTroche/> that has continued to conduct R&D internally as well as through collaborations.<ref>{{cite news|title=Three Years After Merger, Genentech R&D Outshines That of Roche's {{!}} GEN News Highlights|url=http://www.genengnews.com/gen-news-highlights/three-years-after-merger-genentech-r-amp-d-outshines-that-of-roche/81246997/?kwrd=Dalcetrapib|work=Genetic Engineering News|date=July 3, 2012|access-date=September 18, 2016|archive-url=https://web.archive.org/web/20170405023846/http://www.genengnews.com/gen-news-highlights/three-years-after-merger-genentech-r-amp-d-outshines-that-of-roche/81246997?kwrd=Dalcetrapib|archive-date=April 5, 2017|url-status=live}}</ref><ref>{{cite web|title=Living 10 Years in the Future|url=http://www.gene.com/scientists|publisher=Genentech|archive-url=https://web.archive.org/web/20160801073259/http://www.gene.com/scientists|archive-date=August 1, 2016}}</ref>

Genentech's research collaborations include:

* In 2008 Genentech entered into a collaboration with Roche and its subsidiary GlycArt to develop [[obinutuzumab]].<ref>{{cite news|last1=Carroll|first1=John|title=Genentech teams with Glycart on antibody program|url=http://www.fiercebiotech.com/biotech/genentech-teams-glycart-on-antibody-program|work=FierceBiotech|date=October 3, 2008|access-date=September 18, 2016|archive-url=https://web.archive.org/web/20170404155446/http://www.fiercebiotech.com/biotech/genentech-teams-glycart-on-antibody-program|archive-date=April 4, 2017|url-status=live}}</ref>
* In February 2010 Genentech entered into a collaboration with [[University of California, San Francisco]] after having worked with them in about fifteen other collaborations, this time to collaborate on small molecule [[drug discovery]] in neurology.<ref>{{cite news|title=UCSF enters drug discovery agreement with Genentech|url=http://www.fiercebiotech.com/biotech/ucsf-enters-drug-discovery-agreement-genentech|work=FierceBiotech|date=February 19, 2010|access-date=September 18, 2016|archive-url=https://web.archive.org/web/20170404155549/http://www.fiercebiotech.com/biotech/ucsf-enters-drug-discovery-agreement-genentech|archive-date=April 4, 2017|url-status=live}}</ref>
* In October 2014 Genentech paid $150M upfront to collaborate with Iowa-based NewLink Genetics on [[checkpoint inhibitor]]s.<ref>{{cite news|last1=Carroll|first1=John|title=Genentech pays $150M upfront to partner on NewLink's immuno-oncology drug|url=http://www.fiercebiotech.com/partnering/genentech-pays-150m-upfront-to-partner-on-newlink-s-immuno-oncology-drug|work=FierceBiotech|date=October 20, 2014|access-date=September 18, 2016|archive-url=https://web.archive.org/web/20160614043146/http://www.fiercebiotech.com/partnering/genentech-pays-150m-upfront-to-partner-on-newlink-s-immuno-oncology-drug|archive-date=June 14, 2016|url-status=live}}</ref> 
* In June 2015 it entered into a wide-ranging partnership with [[The Data Incubator]] to help train and hire the next generation of data scientists at the company.<ref>{{cite news |title=The Promise and Challenge of Big Data for Pharma |url=https://hbr.org/2016/11/the-promise-and-challenge-of-big-data-for-pharma |access-date=April 5, 2017 |archive-url=https://web.archive.org/web/20170405171004/https://hbr.org/2016/11/the-promise-and-challenge-of-big-data-for-pharma |archive-date=April 5, 2017 |url-status=live }}</ref>
* In January 2015 it signed a $60M deal with [[23andMe]] that gave Genentech access to the genomic and patient-reported data held by 23andMe.<ref>{{cite news|last1=Herper|first1=Matthew|title=Surprise! With $60 Million Genentech Deal, 23andMe Has A Business Plan|url=https://www.forbes.com/sites/matthewherper/2015/01/06/surprise-with-60-million-genentech-deal-23andme-has-a-business-plan/#28855bf37927|work=Forbes|access-date=August 16, 2017|archive-url=https://web.archive.org/web/20170816224058/https://www.forbes.com/sites/matthewherper/2015/01/06/surprise-with-60-million-genentech-deal-23andme-has-a-business-plan/#28855bf37927|archive-date=August 16, 2017|url-status=live}}</ref>
* In October 2015 it started a collaboration with Nimbus Therapeutics to develop leads from Nimbus' [[Drug design#Computer-aided drug design|in silico drug discovery]] platform.<ref>{{cite news|last1=Garde|first1=Damian|title=Genentech co-signs Nimbus' computer-aided R&D with an oncology pact|url=http://www.fiercebiotech.com/partnering/genentech-co-signs-nimbus-computer-aided-r-d-an-oncology-pact|work=FierceBiotech|date=October 20, 2015|access-date=September 18, 2016|archive-url=https://web.archive.org/web/20160711042119/http://www.fiercebiotech.com/partnering/genentech-co-signs-nimbus-computer-aided-r-d-an-oncology-pact|archive-date=July 11, 2016|url-status=live}}</ref>
* In June 2016 Genentech partnered Epizyme to conduct clinical trials exploring whether Epizyme's EZH2 inhibitor [[tazemetostat]] would be synergistic with Genentech's [[atezolizumab]].<ref>{{cite news|last1=Lawrence|first1=Stacy|title=Epizyme nabs combo trial deal with Genentech for NHL candidate {{!}} FierceBiotech|url=http://www.fiercebiotech.com/biotech/epizyme-nabs-combo-trial-deal-genentech-for-nhl-candidate|work=www.fiercebiotech.com|date=June 23, 2016|access-date=September 18, 2016|archive-url=https://web.archive.org/web/20160906121630/http://www.fiercebiotech.com/biotech/epizyme-nabs-combo-trial-deal-genentech-for-nhl-candidate|archive-date=September 6, 2016|url-status=live}}</ref>
* In August 2016, the company began a collaboration with Carmot Therapeutics in which Carmot will  [[drug discovery|discover new candidates]] and Genentech will [[drug development|develop]] them.<ref>{{Cite journal|last=<!--journal staff-->|date=August 2016|title=Carmot to Use Lead-Identification Technology in Collab with Genentech|department=News: Discovery & Development|journal=[[Gen. Eng. Biotechnol. News|Genetic Engineering & Biotechnology News]]|type=Paper|volume=36|issue=14|page=17}}</ref>
* In September 2016 Genentech partnered with the Israeli company [[BioLineRx]] on a [[checkpoint inhibitor]] that Genentech intended to pair with its own [[atezolizumab]].<ref>{{cite news|last1=Lawrence|first1=Stacy|title=Genentech, BioLineRx pair up a checkpoint inhibitor combo|url=http://www.fiercebiotech.com/biotech/genentech-biolinerx-pair-up-a-checkpoint-inhibitor-combo|work=FierceBiotech|date=September 7, 2016|access-date=September 18, 2016|archive-url=https://web.archive.org/web/20160911013920/http://www.fiercebiotech.com/biotech/genentech-biolinerx-pair-up-a-checkpoint-inhibitor-combo|archive-date=September 11, 2016|url-status=live}}</ref>